首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (4): 537-543.doi: 10.3969/j.issn.1006-7795.2015.04.005

• 肺癌专题 • 上一篇    下一篇

高危早期周围型非小细胞肺癌的治疗选择:亚肺叶切除、立体定向消融放射治疗、还是射频消融?

刘宝东   

  1. 首都医科大学宣武医院胸外科, 北京 100053
  • 收稿日期:2015-05-28 出版日期:2015-08-21 发布日期:2015-07-17
  • 基金资助:
    北京市科委首都临床特色应用研究(Z131107002213180)。

Approaching the igh risk patients with early stage non-small cell lung cancer: Sublobar resection, stereotactic ablative radiotherapy, or radiofrequency ablation?

Liu Baodong   

  1. Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
  • Received:2015-05-28 Online:2015-08-21 Published:2015-07-17
  • Supported by:
    This study was supported by Beijing Municipal Science and Technology Commission Capital Characteristic Clinical Application Research(Z131107002213180).

摘要: 亚肺叶切除是治疗高危早期周围型非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的首选,而对于不能手术的患者,可以选择非手术治疗,如立体定向消融放射治疗(stereotactic ablative radiotherapy,SABR)和射频消融(radiofrequency ablation,RFA)。目前研究证实,在高危患者中,SABR和RFA的合并症发生率低和恢复快,且与亚肺叶切除等效,但是还需要前瞻性临床研究。

关键词: 高危, 非小细胞肺癌, 治疗

Abstract: Sublobar(segmental or wedge) resection is the preferred approach for high-risk patients with clinical stage I non-small cell lung cancer. Nonoperative therapies, such as stereotactic ablative radiotherapy(SABR) or radiofrequency ablation(RFA) should be reserved for surgically inoperable patients. SABR and RFA may be clinically equivalent to sublobar resection for the high-risk patients because of lower procedural morbidity and more rapid return to normal function; However, this has not yet been determined in prospective studies.

Key words: high risk, non-small cell lung cancer, treatment

中图分类号: